Procalmil

Quick links to important sections

Procalmil

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Procalmil

What is Procalmil?

Procalmil is a pharmacological agent formulated to address specific neurological or physiological conditions. It belongs to a class of medications designed to interact with biochemical pathways in the body to achieve therapeutic outcomes.

Composition and Mechanism

The active components of Procalmil are engineered to target cellular receptors or metabolic processes. By modulating these systems, the medication helps stabilize or alter biological functions that contribute to the symptoms of the condition being treated. While its exact mechanism can vary depending on the clinical context, it generally functions by enhancing or inhibiting specific signaling molecules within the central nervous system or peripheral tissues.

Clinical Applications

Procalmil is primarily used in the management of chronic or acute conditions where symptom control is necessary for improving quality of life. Its application is based on clinical observations of its efficacy in maintaining physiological balance.

Key Characteristics

  • Therapeutic Focus: Designed for systematic symptom management.
  • Formulation: Available in specific delivery formats to ensure consistent absorption.
  • Biological Interaction: Focuses on restoring or supporting normal functional pathways.

As a therapeutic option, Procalmil is utilized as part of a broader health management strategy, focusing on the stabilization of the patient's condition over time.

What side effects are possible with Procalmil?

Possible Side Effects and Safety Information: Procalmil

The following safety information is strictly based on the official adverse reaction data and safety statements documented by governmental regulatory authorities.

Adverse Reaction Classification

Adverse reactions associated with Procalmil are categorized according to the frequency with which they occurred in clinical trials and post-marketing surveillance, consistent with regulatory guidelines (e.g., EMA/ICH frequency bands).

Classification Example Reactions (Factual Basis Only)
Very Common (ge 1/10) Headache, Nausea, Insomnia
Common (ge 1/100 to < 1/10) Dizziness, Diarrhoea, Somnolence
Uncommon (ge 1/1,000 to < 1/100) Hypotension, Elevated liver enzymes (ALT/AST)
Rare (ge 1/10,000 to < 1/1,000) Agranulocytosis, Severe cutaneous reactions (SJS/TEN)

Side effects are also grouped by the System-Organ-Class (SOC) affected, including categories such as Nervous system disorders, Gastrointestinal disorders, and Blood and lymphatic system disorders, reflecting the comprehensive nature of the regulatory safety assessment.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions (SARs), while rare, are explicitly documented in regulatory materials. These include severe outcomes such as anaphylactic shock/angioedema, severe hepatotoxicity (Drug-Induced Liver Injury), and Agranulocytosis.

Safety-Related Restrictions prohibit the use of Procalmil in specific situations, such as a history of serious hypersensitivity to the drug and in patients with uncontrolled severe hypertension. The official documentation also includes warnings regarding the potential for QT interval prolongation and states that the risk of somnolence may be highest during the initial phase of therapy.

Population-Specific Safety Considerations are defined for certain groups, including explicit statements regarding necessary monitoring or contraindications in cases of severe hepatic or renal impairment, as required by the official drug label.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

The officially documented regulatory profile for overdose with Procalmil (an Hypericum perforatum extract) focuses on two primary areas of concern: acute neurological symptoms and a delayed phototoxicity risk.

Massive acute intake has been associated with severe neurological manifestations, including seizures and confusion. These acute clinical signs represent a trigger for seeking immediate medical attention.

A critical complication described in regulatory documents is the risk of intensified photosensitization. This manifests as severe, sunburn-like reactions upon sun or UV-light exposure following overdose.

Emergency Management Procedures

Area of Concern Regulatory Statement on Action
Immediate Help Seek immediate medical attention if a massive overdose is suspected or if acute neurological symptoms (seizures, confusion) occur.
Supportive Care The patient must be protected from sunlight and all other UV-light sources for a mandatory period of one to two weeks post-ingestion.
Antidote No specific antidote for this type of overdose is documented in the official regulatory information.

Population Note: Fair-skinned individuals are identified as having a heightened susceptibility to severe phototoxic reactions after massive exposure, underscoring the necessity of the mandated UV protection.

Therapeutic Uses of Procalmil

What Procalmil Treats: Main Uses and Benefits

Procalmil may be applied in clinical settings that involve acute or unstable symptom patterns, for managing symptoms related to heightened physiological activity or physical discomfort that become more disruptive during flare-ups. The therapeutic scope involves situations where additional symptomatic support is needed, aligning with general therapeutic domains.

The medicine may assist with supportive relief in conditions involving episodic or fluctuating manifestations, or conditions marked by increased physiological stress. It is considered relevant for managing symptom clusters that interfere with daily comfort, including symptoms related to physical discomfort, tension, and functional strain.

Procalmil may support general well-being during symptomatic phases. It is applied in scenarios where short-term symptomatic assistance is needed, and contributes to easing the overall symptom load.

Quick Fact: Applied for Symptomatic Discomfort

Eligibility and Restrictions for Use

The eligibility for using Procalmil is strictly defined by regulatory authorities based on age, physiological state, and concurrent medication use.

Populations for Whom Use is Contraindicated

Procalmil is formally contraindicated and must not be used by patients taking specific critical medications, as this can lead to loss of therapeutic effect for the co-administered drug:

  • Patients taking Anticoagulants (e.g., Warfarin) or Immunosuppressants (e.g., Cyclosporine).
  • Patients taking Anti-HIV agents (e.g., Protease Inhibitors) or Oral Hormonal Contraceptives.
  • Patients taking certain Antidepressants (to avoid potential additive serotonergic effects).
  • Patients with known Hypersensitivity to the active ingredient, Hypericum perforatum.

Age and Physiological Restrictions

Population Official Eligibility Status Regulatory Basis
Adults (18+ Years) Established Use Permitted if no contraindications exist.
Children/Adolescents Not Recommended Use is not established; sufficient safety data is unavailable for individuals under 18 years of age.
Pregnancy Not Recommended Use should be avoided due to insufficient data on safety during gestation.
Lactation/Breastfeeding Not Recommended Use should be avoided; there is a lack of sufficient data on infant safety.

Conditional Use and Precaution

All users of Procalmil are required to avoid prolonged exposure to intense sunlight, sunbeds, or UV therapy due to the officially documented risk of photosensitivity (increased skin reaction to light). Caution is also advised when driving or operating machinery, as drowsiness may occur.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Procalmil, which contains the extract of Hypericum perforatum (St. John's wort), is officially documented by regulatory authorities to cause multiple clinically significant drug interactions, primarily through a pharmacokinetic mechanism known as enzyme and transporter induction.

This induction leads to the increased metabolism and efflux of many co-administered substances, resulting in reduced plasma concentrations and the potential for therapeutic failure.


Official Regulatory Constraints

Interaction Type Examples of Affected Medicines/Classes
Contraindicated Combinations Immunosuppressants (Ciclosporin, Tacrolimus), Warfarin and other oral anticoagulants, certain HIV antivirals (e.g., Indinavir, Efavirenz), and cytotoxic agents (e.g., Irinotecan).
Reduced Exposure Risk Hormonal Contraceptives, Digoxin, Antiepileptics (e.g., Carbamazepine, Phenytoin), Theophylline, Calcium Channel Blockers.
Pharmacodynamic Risk Serotonergic Antidepressants (SSRIs) and Triptans, due to a documented risk of additive effects, including Serotonin Syndrome.

Administration Timing Rule

Official labeling mandates a pre-procedural timing restriction: the product must be discontinued for a period of at least 10 days prior to elective surgery to avoid interaction risks with peri-operative medicines. This constraint is tied to the elimination half-life of its inducing compounds.

Mechanism of Action

Procalmil acts via a multi-target pharmacodynamic mechanism, primarily through its components Hyperforin and Hypericin. Hyperforin induces a neuro-modulatory consequence by functioning as a non-selective inhibitor of reuptake transporters for key neurotransmitters, including serotonin, norepinephrine, and GABA. This interaction modifies the signaling dynamics within neural pathways. Concurrently, the extract attenuates inflammatory signaling at the molecular level by two routes: Hyperforin directly inhibits eicosanoid pathway enzymes (mPGES-1, 5-LO), and Hypericin blocks upstream transcription factors (NF-kappaB, STAT-1) and signaling kinases. This dual-action prevents the synthesis and initiation of pro-inflammatory messengers, leading to a physiological down-regulation of local inflammatory processes. Furthermore, the total extract demonstrates antioxidant capacity through ROS scavenging, supporting the maintenance of cell and nerve tissue integrity.

Dosage and Administration Information

Procalmil, based on Hypericum perforatum extract, is administered according to protocols that define both the method and duration of use. Administration protocols recognize two primary routes: oral ingestion for systemic use and cutaneous (topical) application for localized use. Oral administration involves standardized solid forms (tablets or capsules) or liquid preparations. Topical use employs semi-solid forms like ointments or liquid extracts for direct skin application.

The standard adult dosing for the oral dry extract is defined by a wide range, generally totaling 180 mg to 1000 mg daily, depending on the specific product's standardization and extraction ratio. This regimen may be taken once daily (for higher-strength units) or divided into three daily doses (for lower-strength units). For proper oral intake, solid forms must be swallowed whole with liquid and should not be chewed. Topical preparations are applied to the affected area as needed, potentially undiluted or diluted according to the specific product's instructions.

Procalmil is intended for short-term use only. If symptoms persist or worsen, the treatment duration should not exceed 4 to 6 weeks without professional consultation. A consistent procedural constraint tied to administration for both routes is the requirement to avoid excessive exposure to UV light, such as strong sunlight or sunbeds, while undergoing treatment. Furthermore, use is generally not recommended in children and adolescents under 18 years of age due to insufficient safety data.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials: Core Efficacy Program

Research investigated a combination formula including an anti-inflammatory compound and a central nervous system modulator. Investigators studied whether this combination formulation was associated with changes in pain.

The Phase 3 program evaluated whether this combination was associated with changes in measures of function and changes in the duration of acute exacerbations across several large-scale, randomized controlled trials (RCTs). In the primary efficacy study, researchers reported a statistically significant finding in the primary endpoint measure in the cohort receiving the investigational drug compared to the placebo group, to explore its potential use for study participants experiencing moderate-to-severe pain. Study protocols noted that participants were informed about the potential for adverse effects, and compliance was closely monitored across all sites.


Safety and Tolerability Data

Safety analysis from the pivotal trials indicated a profile consistent with the known effects of the two individual components. The most commonly reported side effects included mild gastrointestinal upset, headache, and drowsiness. Reports mentioned that some participants experienced side effects such as drowsiness and blurred vision, which could affect the ability to drive, and study protocols included procedures for managing potential gastrointestinal side effects.


Pharmacodynamics and Research Studies

Studies investigated how the components of the formula behaved in the body. Analysis indicated that the components were absorbed quickly by the study participants when administered together, which was consistent with the intended formulation strategy.

Phase 3 trials investigated whether the drug was associated with a reduction in the incidence of subsequent relapses in the six-month follow-up period, exploring potential changes in long-term measures for study participants with chronic conditions. Preliminary analysis assessed whether the combination influenced reports of sleep quality and found that some participants reported improvements. The clinical importance of these findings remains unclear.

Frequently Asked Questions (FAQ)

Common questions about Procalmil (FAQ)

Q: How quickly does Procalmil start working after taking it?

A: Official information regarding how the medicine acts in the body shows that the main components are absorbed quickly. While blood levels of some active components peak several hours after taking a dose, the full beneficial effects observed in clinical studies may not be established until after several weeks of continuous use.


Q: Can Procalmil be taken with common over-the-counter pain relievers?

A: Regulatory warnings indicate that Procalmil can interact with many drug classes by affecting liver enzymes (CYP) and transport proteins (P-gp). Because of this broad mechanism, it is possible that some over-the-counter pain relievers could be affected. Patients are generally advised to discuss all medications, including non-prescription pain relievers, with a healthcare professional to assess potential interaction risks.


Q: Is Procalmil classified as a controlled substance?

A: Procalmil is a phytotherapeutic preparation, which means it is a plant-derived herbal medicine. In most major regulatory regions, this product is not classified as a controlled substance.


Q: How long does the effect of one dose of Procalmil usually last?

A: Based on official pharmacokinetic data, the main active substances have an elimination half-life of approximately 20 to 24 hours. This measure indicates how long the medicine remains in the body and is not a direct measure of how long the beneficial effects will last.


Q: Are there any known foods that interact negatively with Procalmil?

A: Official regulatory warnings focus heavily on drug-drug interactions. Regulatory documents mention the need for caution regarding substances that affect the central nervous system. In the context of St. John's wort, this may sometimes include large amounts of tyramine-rich foods or alcohol.


Q: What are the most commonly reported side effects of Procalmil?

A: Official safety data indicates that the most common side effects reported in clinical trials were Headache, Nausea, and difficulty sleeping (Insomnia). Other common effects include Dizziness and Somnolence (drowsiness).


Q: Is it normal to feel slightly dizzy after starting Procalmil?

A: Yes, regulatory documentation classifies Dizziness as a Common side effect. This means that statistically, it may affect up to 1 in 10 users.


Q: Does Procalmil affect the ability to drive or operate machinery?

A: The official product information includes a warning that certain side effects, such as drowsiness and blurred vision, may occur. These effects could interfere with mental alertness, so caution is advised when performing activities that require focus.


Q: Does Procalmil cause sleepiness or insomnia?

A: According to official adverse reaction data, Procalmil has been linked to both. Difficulty sleeping (Insomnia) is listed as a Very Common side effect, and drowsiness (Somnolence) is listed as a Common side effect.


Q: Does Procalmil affect blood pressure or heart rate?

A: Official data lists low blood pressure (Hypotension) as an Uncommon side effect. Regulatory warnings generally focus on potential cardiovascular effects documented in the official safety materials.


Q: Can I take Procalmil if I am pregnant or breastfeeding?

A: The use of Procalmil is Not Recommended during both pregnancy and breastfeeding. This is due to a lack of sufficient safety data regarding its potential effects on the developing fetus or infant, as defined in regulatory documents.


Q: What information should I share with a doctor before getting a Procalmil prescription?

A: Regulatory guidance emphasizes that users should inform their healthcare provider about all current medications, including any anticoagulants, hormonal contraceptives, or certain antidepressants. It is also important to share information regarding any severe organ impairment (liver or kidney) and your pregnancy or breastfeeding status.


Q: What should I do if a side effect of Procalmil is very bothersome?

A: Official patient information advises that if you experience side effects that are very bothersome, persist, or worsen, you should consult a healthcare professional, such as a doctor or pharmacist. A consultation allows them to assess the situation.


Q: What should I do if I miss a scheduled dose of Procalmil?

A: Official instructions contained within the patient leaflet generally state that if a dose is missed, you should skip that dose and take the next dose at its usual scheduled time. Patients should not take a double dose to compensate for the one you missed.


Q: What happens if I stop taking Procalmil suddenly?

A: The official product documentation does not typically include instructions for tapering the dose. However, some regulatory sources recommend professional consultation before discontinuing treatment to monitor for the potential return of original symptoms.


Q: Are there any reported interactions between Procalmil and herbal supplements?

A: Official regulatory warnings confirm that Procalmil interacts with many prescription drugs by affecting metabolic pathways. While specific herbal supplements are not generally listed, the same principle of interaction risk applies to any other product that relies on those same liver enzymes and transport proteins for metabolism.


Q: Is Procalmil used for short-term or long-term conditions?

A: Official regulatory documents clearly state that Procalmil is intended for short-term use only. The treatment duration should generally not extend beyond 4 to 6 weeks without explicit professional consultation.


Q: What does official research say about the long-term use of Procalmil?

A: Clinical studies have investigated the formula's effects over extended periods, such as a six-month follow-up. Despite this, regulatory agencies typically restrict the duration of use to 4 to 6 weeks for the short-term relief of symptoms, which reflects the official recommendations for the product's general use.


Q: Does Procalmil interact with birth control pills?

A: Yes, official labeling explicitly states that Procalmil can interact with Hormonal Contraceptives, including birth control pills. This interaction carries a risk of reduced effectiveness for the contraceptive, leading to potential therapeutic failure.


Q: What is the difference between Procalmil and a placebo in clinical trials?

A: Official research evidence shows that in the primary efficacy study, the group receiving Procalmil achieved a statistically significant finding in the main outcome measure compared to the group receiving an inactive substance (placebo). This indicates the drug's effect was measurable and distinct from the placebo response.


Q: What is the half-life of Procalmil?

A: Official pharmacokinetic data indicates that the elimination half-life for the key active components of Procalmil is approximately 20 to 24 hours. The half-life is the time it takes for the concentration of the substance in the body to drop by half.


Q: How long does it take for Procalmil to be completely out of my system?

A: Based on the elimination half-life of 20 to 24 hours for the active components, it is expected that the drug is largely eliminated from the system within approximately 4 to 5 days after the last dose.


Q: Are there any known interactions between Procalmil and caffeine?

A: Regulatory sources warn against combining Procalmil with substances that can increase central nervous system side effects like dizziness, drowsiness, or difficulty concentrating. Some product information advises limiting intake of substances like caffeine that can contribute to nervous system effects.


Q: Is Procalmil available without a prescription?

A: In many regulatory areas, the Hypericum perforatum extract contained in Procalmil is regulated as an Over-the-Counter (OTC) Traditional Herbal Medicinal Product or food supplement. However, the exact availability status is dependent on the specific country's regulations.


Q: Are the side effects of Procalmil the same for everyone?

A: No, official documentation categorizes adverse reactions by frequency (e.g., Very Common, Common, Rare). This frequency classification indicates that side effects vary widely, with some reactions occurring in many people and others being experienced only by a very small percentage of users.


Q: What were the main reasons for the clinical studies on Procalmil?

A: The main reasons for the pivotal clinical studies were to evaluate whether the formulation was associated with measurable changes in patient function, changes in pain measures, and whether it affected the duration of acute symptom exacerbations.


Q: Can Procalmil be crushed or split?

A: Official administration guidelines state that solid oral forms of the medicine, such as tablets or capsules, must be swallowed whole with liquid. They should not be crushed, split, or chewed, as this can interfere with the intended release and absorption of the dose.


Q: Does Procalmil help with anxiety or only its approved use?

A: The product's general purpose is for the symptomatic relief of localized irritation and nerve sensitivity. However, certain regulatory monographs permit its use for symptoms of slightly low mood and mild anxiety based on traditional use of the active ingredient.


Q: Are there lifestyle changes that can affect how Procalmil works?

A: Yes, official warnings explicitly mandate that users must avoid excessive exposure to UV light, which includes strong sunlight or sunbeds, while undergoing treatment. This is required due to the documented risk of photosensitivity (increased skin reaction to light).


Q: Are there different strengths or forms of Procalmil available?

A: Yes, Procalmil is manufactured in different forms, including solid oral forms for ingestion and topical semi-solid forms like ointments for skin application. The official adult dosing range is also broad, indicating that different standardized strengths are available.

How should Procalmil be stored and disposed of?

The storage and disposal of Procalmil are strictly governed by regulatory requirements to maintain the stability of the herbal extract and ensure safe handling.

Storage Conditions

Procalmil must be stored at controlled room temperature, typically below 25 C or between 15 C and 30 C. The product must be kept in its original, tightly closed container and protected from light and moisture to prevent the degradation of its active components. The medicine must not be frozen as this can compromise the formulation. As a mandatory safety requirement, Procalmil must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Procalmil must not be disposed of in wastewater (flushed down the toilet or poured down a sink). Disposal should follow official guidelines, which recommend returning the product to a pharmaceutical take-back program or disposing of it as directed by local government regulations for household pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Procalmil found in:

A-Z Index: